Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Volatility & Risk
Tarsus Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Earnings & Valuation
This table compares Tarsus Pharmaceuticals and Monopar Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $366.10 million | 7.33 | -$115.55 million | ($2.02) | -31.31 |
| Monopar Therapeutics | N/A | N/A | -$15.59 million | ($3.44) | -17.22 |
Monopar Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Tarsus Pharmaceuticals and Monopar Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 1 | 1 | 5 | 2 | 2.89 |
| Monopar Therapeutics | 1 | 0 | 10 | 2 | 3.00 |
Tarsus Pharmaceuticals presently has a consensus price target of $82.29, indicating a potential upside of 30.10%. Monopar Therapeutics has a consensus price target of $107.00, indicating a potential upside of 80.62%. Given Monopar Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Monopar Therapeutics is more favorable than Tarsus Pharmaceuticals.
Profitability
This table compares Tarsus Pharmaceuticals and Monopar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -22.17% | -26.29% | -17.02% |
| Monopar Therapeutics | N/A | -25.72% | -24.81% |
Summary
Monopar Therapeutics beats Tarsus Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
